Nyrada Inc. (ASX:NYR)

Australia · Delayed Price · Currency is AUD

0.7450

+0.0050 (0.68%)

Aug 21, 2026, 3:57 PM AEST

175.93% (1Y)

Market Cap	183.94M +186.5%
Revenue (ttm)	2.38M +44.3%
Net Income	-5.58M
EPS	-0.03
Shares Out	246.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	336,971
Open	0.7900
Previous Close	0.7400
Day's Range	0.7450 - 0.8000
52-Week Range	0.2250 - 1.4350
Beta	0.92
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Nyrada

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Country United States

Stock Exchange Australian Securities Exchange

Ticker Symbol NYR

Full Company Profile

Financial Performance

In fiscal year 2025, Nyrada's revenue was 2.40 million, a decrease of -26.07% compared to the previous year's 3.24 million. Losses were -4.85 million, 248.3% more than in 2024.

Financial Statements